Evidence map›Paper›PMID 39007081›Full record

ArticleIBRO neuroscience reports2024

Risk of depression after Parkinson's disease, stroke, multiple sclerosis, and migraine in an Iranian population and assess psychometric characteristics of three prevalent depression questionnaires.

Mehri Salari, Hossein Pakdaman, Masoud Etemadifar, Fatemeh HojjatiPour, Maede Khalkhali, Nima Mirjamali, Arash Hossein Abadi Farahani

Abstract read
In one paragraph

Article in IBRO neuroscience reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mehri SalariBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein PakdamanBrain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Masoud EtemadifarDepartment of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh HojjatiPourStudent Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Shahid Beheshti Medical University, Tehran, Iran.
Maede KhalkhaliStudent Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Shahid Beheshti Medical University, Tehran, Iran.
Nima MirjamaliStudent Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Shahid Beheshti Medical University, Tehran, Iran.
Arash Hossein Abadi FarahaniStudent Research Committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Shahid Beheshti Medical University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: We aim to evaluate the prevalence of depression in disorders including multiple sclerosis (MS), Parkinson's disease (PD), migraine, and stroke. Also, we detect risk factors for depression occurrence within each disorder. Moreover, we compare the risk factors in these four common neurologic disorders. In advance, we assess the three surveys in order to better comprehend their distinctions. Background: Depression is a globally prevalent Psychologic disorder and common co-morbidity in neurological diseases. However, it is mostly underdiagnosed in chronic patients and causes numerous adverse effects. Methods: We used the database of neurology specialty clinics in a hospital in Tehran, the largest city of Iran. Five hundred nineteen patients, including 105 PD patients, 101 patients with stroke, 213 cases with MS, and 100 Migraine patients, were assessed. They were asked about their chief characteristics and disease-specific variables that may cause depression. Moreover, depression criteria were measured with three internationally used scales to study their variances. Results: Overall, the prevalence of depression in PD, stroke, MS, and migraine, according to the BDI-II scale, were 43.8%, 38.6%, 45.1%, 37.6%, and according to HDRS scale, were 56.2%, 51.5%, 39.4%, and 43.6% respectively. Finally, according to DSM-XC the depression prevalence were 64.8%, 34.7%, 36.2%, and 67.3% respectively. Possible risk factors of depression were lower educational level, disease severity, socioeconomic level, marital or employment status, female gender, higher age, and consumption of some specific drugs. Conclusion: Depression is a widespread disorder in chronic neurologic conditions. Our data suggests the odds of depression in neurologic disorders depend on the characteristics of the patient and the features of the disease.

Indexed as

DepressionMigraineMultiple SclerosisParkinson DiseaseStroke

Identifiers

PMID39007081
PMCPMC11240298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.